Market open
NewAmsterdam Pharma Company N.V./$NAMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Ticker
$NAMS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
68
Website
NAMS Metrics
BasicAdvanced
$1.8B
-
-$2.56
-0.06
-
Price and volume
Market cap
$1.8B
Beta
-0.06
52-week high
$26.95
52-week low
$14.06
Average daily volume
1.2M
Financial strength
Current ratio
8.075
Quick ratio
7.848
Long term debt to equity
0.027
Total debt to equity
0.059
Management effectiveness
Return on assets (TTM)
-18.19%
Return on equity (TTM)
-46.20%
Valuation
Price to revenue (TTM)
33.673
Price to book
2.32
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
-9.635
Growth
Revenue change (TTM)
223.37%
Earnings per share change (TTM)
18.90%
3-year earnings per share growth (CAGR)
-12.38%
NAMS News
AllArticlesVideos
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·3 weeks ago
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?
NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $1.8B as of April 22, 2025.
What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?
The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of April 22, 2025.
Does NewAmsterdam Pharma Company N.V. stock pay dividends?
No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of April 22, 2025.
When is the next NewAmsterdam Pharma Company N.V. dividend payment date?
NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.
What is the beta indicator for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.